Recently, Jincheng Pharm (300233) responded to investors' questions on the investor interaction platform. British American Tobacco announced plans to launch a synthetic nicotine e-cigarette, which has attracted the attention of the market and investors. Some investors asked about the impact of this plan on Jincheng Pharm and whether British American Tobacco is one of its clients.
Jincheng Pharm company responded by stating that the current plan has no significant impact on the company, and they have not confirmed if there is any business dealings with British American Tobacco.
At the same time, investors have inquired with Jincheng Pharm regarding the potential use of nicotine as a raw material for anti-aging medication.
In response, Jincheng Pharmaceutical Company stated that currently the company's nicotine is mainly used in the e-cigarette industry, but they will continue to monitor research developments in other fields. This statement has sparked speculation and attention from the market about the company's future direction.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
